Clinical trials: asthma
Asthma
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)
This study aims to generate additional safety data on the propellant component of the reformulated product by comparing metered dose inhaler (MDIs) containing HFA-152a (test) with HFA-134a (reference).
- Trial name
- NCT07645248
- Testing
- HFA-152a, HFA-134a
- Where
- 20 sites in United States, Argentina and 2 more
- Volunteers
- 110 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101)
The aim of this study is to compare the efficacy of ciclesonide with respect to reduction of the number of asthma exacerbations in children with mild persistent asthma.
- Trial name
- POPCICLE (NCT00163293)
- Testing
- Ciclesonide
- Where
- 7 sites in Canada, Hungary and 1 more
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Asthma, Diabetes Mellitus
A Study Designed to Determine if the Pharmacokinetic Disposition of Inhaled Insulin Exposure is the Same for Asthmatics and Non-asthmatics
This study will compare the rate and extent of absorption of TI Inhalation Powder in subjects with asthma and subjects with normal lung function. 24 eligible subjects will be enrolled into the treatment phase of the trial.
- Trial name
- NCT00673621
- Testing
- Technosphere Insulin Inhalation Powder, Salbutamol (Albuterol), Methacholine chloride
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Asthma
SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults
The purpose of this study is to compare Symbicort Single Inhaler treatment with the Best Conventional Practice in patients with persistent asthma
- Trial name
- NCT00238784
- Testing
- Budesonide/formoterol Turbuhaler
- Where
- 3 sites in Canada
- Volunteers
- 1,300 people
- Sponsor
- AstraZeneca
Severe Eosinophilic Asthma
Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)
Benralizumab is a humanised, afucosylated, monoclonal antibody against the interleukin (IL)-5 receptor (IL-5R) α subunit that induces direct, rapid, and near-complete depletion of eosinophils in blood, airway tissue, and bone…
- Trial name
- NCT05271526
- Where
- Russia
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
Asthma
An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma
This study is designed to compare the effectiveness and safety of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444) or 200mcg Fluticasone Furoate…
- Trial name
- NCT01706198
- Testing
- fluticasone furoate + vilanterol, inhaled corticosteroid with or without a long acting beta2-agonist
- Where
- 180 sites in United Kingdom
- Volunteers
- 4,233 people
- Sponsor
- GlaxoSmithKline
Asthma
XC8 Safety, Tolerability and Pharmacokinetics in Healthy Volunteers
A double-blind, randomized, placebo-controlled, Phase I clinical study of the safety and tolerability of increasing doses of XC8 after single and repeated oral administration in healthy volunteers.
- Trial name
- NCT03441815
- Testing
- XC8
- Where
- Russia
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- PHARMENTERPRISES LLC
Pulmonary Disease, Chronic Obstructive
A Prospective Cohort Study of Asthma and COPD Overlap in Japanese COPD Patients Using the Diagnostic Criteria of The Japanese Respiratory Society
This study is a multicentered and non-interventional prospective cohort study. Study centers shall be the institutions where the examinations, adopted in the ACO diagnostic criteria9) from The Japanese Respiratory Society, are…
- Trial name
- ACO-Registry (NCT03577795)
- Where
- Japan
- Volunteers
- 710 people
- Sponsor
- AstraZeneca
Moderate Asthma
A Study to Assess Pharmacokinetics, Safety and Tolerability of Multiple Doses of CAT-354 in Subjects With Moderate Asthma
The study includes participants with moderate asthma who were randomly assigned to receive the study medication (CAT-354) or placebo.
- Trial name
- NCT00974675
- Testing
- CAT-354 1mg/kg, CAT-354 5 mg/kg, CAT-354 10mg/kg
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- MedImmune LLC
Asthma
A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma
The purpose of this study is to demonstrate improvement of peripheral airway resistance (R5-R20) from baseline with fluticasone/formoterol breath actuated inhaler (BAI).
- Trial name
- NCT02753712
- Testing
- Fluticasone/Formoterol BAI, Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)
- Where
- 16 sites in Australia, New Zealand and 3 more
- Volunteers
- 105 people
- Sponsor
- Mundipharma Research Limited
Asthma
To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma
This study will investigate the effects of altering the time of day of dosing (morning or evening) with Fluticasone Furoate 100 (FF 100) micrograms (mcg) once daily administered via a dry powder inhaler (DPI) in subjects with…
- Trial name
- NCT01808339
- Testing
- Fluticasone Furoate (FF)
- Where
- Australia
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Asthma
Safety, Tolerability and Pharmacokinetics of ASM-024 Administered to Healthy Subjects and Subjects With Moderate Asthma
The purpose of this study is to evaluate the safety and tolerability of the dry powder formulation of ASM-024 following single and multiple administration by inhalation of ascending doses in healthy subjects and subjects with…
- Trial name
- NCT01793298
- Testing
- ASM-024
- Where
- 2 sites in Canada
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Asmacure Ltée
Asthmatic
Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder
The study is aimed to assess the dose proportional total systemic exposure (when the administration is without the activated charcoal) to B17MP (active metabolite of BDP) and its lung bioavailability (when the administration is…
- Trial name
- NCT01738087
- Testing
- NEXThaler 100/6 mcg DPI, Flixotide Accuhaler 500 mcg, NEXThaler 200/6 mcg DPI
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma
A Safety, Efficacy, and Tolerability Study of Daily Dosing with Levalbuterol Tartrate HFA MDI and Placebo in Subjects Aged Birth to <48 Months with Asthma.
- Trial name
- NCT00809757
- Testing
- Levalbuterol, Levalbuterol UDV TID
- Where
- 46 sites in United States
- Volunteers
- 197 people
- Sponsor
- Sumitomo Pharma America, Inc.
Asthma
Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma
This study is a multicenter, stratified, randomized, active control, double-blinded, parallel-group comparative study with an open-label extension period.
- Trial name
- NCT02113436
- Testing
- FP/ SLM HFA MDI 50/25 mcg, FP HFA MDI 50 mcg
- Where
- 69 sites in Japan
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Asthma
Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 y) (BY9010/M1-506)
The aim of the study is to compare the efficacy of two doses of a fixed combination of ciclesonide/formoterol fumarate versus ciclesonide alone versus formoterol fumarate alone in patients with asthma.
- Trial name
- NCT00314509
- Testing
- Ciclesonide/Formoterol Combination
- Where
- 26 sites in France, Germany and 2 more
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Asthma
Study in Adult Patients With Moderate to Severe Asthma
This study assessed the influence of pink vs. white pressurized metered-dose inhaler (pMDI) actuators on asthma symptoms perception. There was no prespecified primary objective.
- Trial name
- FEEL (NCT04886999)
- Testing
- Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler A), Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler B)
- Where
- 10 sites in Italy
- Volunteers
- 78 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011)
The purpose of this study is to evaluate the effect of MK-1029 on lung function in the treatment of adults who have persistent asthma that is uncontrolled with the use of montelukast (ML).
- Trial name
- NCT01624974
- Testing
- MK-1029, Montelukast (ML)
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device
This study will assess the pharmacodynamics, safety, tolerability and pharmacokinetics of two different formulations of indacaterol maleate, both administered via the Concept1 device.
- Trial name
- NCT01484197
- Testing
- 75 µg indacaterol maleate (LB), 75 µg indacaterol maleate (PoS), 37.5 µg indacaterol maleate (PoS)
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Investigation Of A New Medication (GW642444) In Asthmatic Patients
This study will evaluate efficacy (FEV1), safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat inhaled doses of GW642444.
- Trial name
- NCT00354874
- Testing
- GW642444, salmeterol 50mcg
- Where
- 3 sites in Germany, Sweden
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline